The arrival of Retatrutide ZPHC, at a strength of 120mg, is creating considerable buzz within the healthcare community. This novel dual GIP and GLP-1 receptor medication seems to offer impressive improvements in body reduction compared to current therapies. Preliminary patient studies have shown marked declines in body fat percentage, conceivably m